Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC FRETS-VWF73 (TFA) | 96.8% | 9340.61 | 500 UG
FRETS-VWF73 (TFA) is a 73-amino-acid peptide that serves as a fluorogenic substrate for the ADAMTS13 assay. This peptide is utilized as a predictive tool for thrombotic thrombocytopenic purpura, offering a valuable resource for research and diagnostic applications.
- 73-amino-acid peptide
- Fluorogenic substrate for ADAMTS13 assay
- Used as a predictive tool for thrombotic thrombocytopenic purpura
- Excitation at 340 nm; emission at 450 nm
Medchemexpress LLC Astressin 2B TFA | 99.5% | 4041.69 (free base) | 5 MG
Astressin 2B TFA | 99.5% | 4041.69 (free base) | 5 MG
Medchemexpress LLC Rf470 TFA | 2369899-34-1 | 624.63 | 25 MG
Rf470 TFA is a FMR-probe-D-lysine conjugate (Max Ex: 470 nM; Max Em: 640 nM) that can be covalently incorporated into peptidoglycan by bacteria. It exhibits extremely weak fluorescence in its free state, but its fluorescence significantly increases when it is catalytically incorporated into peptidoglycan by transpeptidases.
- Can be used for real-time monitoring of peptidoglycan biosynthesis.
- Can be used for detection of transpeptidase activity.
- Can be used for screening of antibiotics through fluorescence changes.
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Sigma Aldrich Fine Chemicals Biosciences Trifluoroacetic acid 99 fo500G
TRIFLUOROACETIC Trifluoroacetic acid 99 fo500G
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 | 100 UG
Clovibactin TFA is the TFA salt form of Clovibactin. It is an antibiotic effective against drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inhibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors.
- Effective against drug-resistant bacterial pathogens
- Exhibits no detectable resistance
- Inhibits cell wall synthesis
- Targets pyrophosphate of peptidoglycan precursors
Medchemexpress LLC Hr97 Tfa | 1518.84 | 1 MG
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops called HR97-SunitiGel. The peptide-drug conjugate can provide sustained ocular drug delivery.
- Cell-penetrating peptide
- Combines with engineered melanin to prepare eye drops
- Supports sustained ocular drug delivery
- Sequence: Phe-Ser-Gly-Lys-Arg-Arg-Lys-Arg-Lys-Pro-Arg-Cys
- Shortened sequence: FSGKRRKRKPRC
- In vitro solubility: 50 mg/mL in DMSO (need ultrasonic)
Medchemexpress LLC NLS-StAx-h TFA | 98.9% | 3559.28 | 1 MG
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide that inhibits Wnt signaling, with an IC50 of 1.4 μM. It effectively inhibits interactions between β-catenin and transcription factors and demonstrates anti-proliferative effects on cancer cells, including SW-480 and DLD-1 colorectal cancer cells.
- Selective, cell permeable, stapled peptide
- Inhibits Wnt signaling with an IC50 of 1.4 μM
- Efficiently inhibits β-catenin-transcription factor interactions
- Shows anti-proliferation of cancer cells
- Inhibits proliferation of colorectal cancer cells (SW-480 and DLD-1 cells) by more than 80% at 10 μM
- Inhibits migration of DLD-1 colorectal cancer cells in a dose-dependent manner
Medchemexpress LLC AH-D peptide TFA | 98.8% | 3283.75 | 5 MG
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
- Antiviral peptide
- Disrupts membrane structures within exosome size range
- Induces T-EXO depletion
- Enhances cancer immunotherapy
- Solid, white to off-white appearance
- Store sealed, away from moisture
- Powder storage at -80°C for 2 years, -20°C for 1 year
- In solvent storage at -80°C for 6 months, -20°C for 1 month
Medchemexpress LLC NNC9204-1177 (TFA) | 98.7% | 4570.07 (free base) | 1 MG
NN1177 TFA is a long-acting GLP-1/glucagon receptor co-agonist. It can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice and reduces CYP3A4 mRNA expression and activity in human hepatocytes. It can also reduce liver fat and inflammatory and fibrosis biomarkers in a NASH mouse model.
- Induces dose-dependent body weight loss in diet-induced obese (DIO) mice.
- Reduces CYP3A4 mRNA expression and activity in human hepatocytes.
- Reduces liver fat and inflammatory and fibrosis biomarkers in a NASH mouse model.
Medchemexpress LLC Gln-AMS (TFA) | 99.9% | 588.47 | 25 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor that inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. It is provided as a solid, white to off-white in appearance, and is stable under recommended storage conditions, making it suitable for laboratory research in metabolic enzyme, protease, anti-infection, and bacterial studies.
- Inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Available in various quantities for research needs.
- Stable under recommended storage conditions.
- Suitable for in vitro and in vivo dissolution protocols.
![Medchemexpress LLC (2S)-2-amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid; TFA | 00-00-0 | 99.8% | 509.45 g·mol⁻¹ | C25H23F4NO6 | 5 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000263712.png-250.jpg)
Medchemexpress LLC (2S)-2-amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid; TFA | 00-00-0 | 99.8% | 509.45 g·mol⁻¹ | C25H23F4NO6 | 5 MG
ALX-1393 TFA is the trifluoroacetate salt of a selective glycine transporter 2 (GlyT2) inhibitor used as a research reagent to investigate glycinergic neurotransmission and nociception. It is supplied as a purified solid for laboratory use and has reported antinociceptive activity in rodent pain models.
- Selective GlyT2 inhibitor for probing glycinergic neurotransmission.
- Research-grade solid suitable for in vitro and in vivo studies.
- High purity (99.83%) supporting reproducible results.
- Molecular formula C25H23F4NO6 and molecular weight 509.45 g·mol⁻¹.
- Store at -20°C to maintain stability and minimize moisture exposure.
Medchemexpress LLC ACV Tripeptide TFA | 477.45 | 25 MG
ACV Tripeptide TFA is a tripeptide that serves as the initial dedicated intermediate in the biosynthetic pathway leading to penicillin and cephalosporin classes of β-lactam natural products in bacteria and fungi. It is nonribosomally synthesized by the ACV synthetase (ACVS) enzyme, encoded by the 11 kb *pchAB* gene, and can be used for the biosynthesis of β-lactam antibiotics. This tripeptide contains the unusual amino acid α-aminoadipic acid (α-AAA), along with L-cysteine and D-valine.
- Tripeptide
- Initial intermediate in β-lactam biosynthesis
- Synthesized by ACV synthetase (ACVS) enzyme
- Contains α-aminoadipic acid (α-AAA), L-cysteine, and D-valine
- Molecular weight: 477.45
- Formula: C16H26F3N3O8S
- Appearance: Solid
Medchemexpress LLC SJ1008030 TFA | 2863634-97-1 | 99.8% | 987.96 | 1 MG
SJ1008030 TFA is a JAK2 PROTAC designed for selective degradation of JAK2. This compound inhibits MHH-CALL-4 cell growth and is suitable for leukemia research. It degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner, indicating inhibition of the JAK-STAT signaling pathway.
- Selectively degrades JAK2
- Inhibits MHH-CALL-4 cell growth with an IC50 of 5.4 nM
- Can be used for leukemia research
- Degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner
- Indicates inhibition of the JAK-STAT signaling pathway
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 (free base) | 1 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist that significantly enhances the activation and proliferation of T cells. It inhibits the migration and metastasis and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling. This compound reduces the expression of MCAM and N-cadherin, making it suitable for studies on acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Vasoactive intestinal polypeptide (VIP receptor) antagonist
- Enhances T cell activation and proliferation
- Inhibits migration and metastasis of melanoma cells
- Induces apoptosis in melanoma tumor cells
- Inhibits VIP-VPAC2 signaling
- Reduces MCAM and N-cadherin expression
- Useful for acute myeloid leukemia (AML) research
- Useful for uveal melanoma (UVM) research